Theodore E. Hebert

Array ( [id] => 16460786 [patent_doc_number] => 10844121 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-11-24 [patent_title] => Antibodies binding LAG-3 and uses thereof [patent_app_type] => utility [patent_app_number] => 16/033465 [patent_app_country] => US [patent_app_date] => 2018-07-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 12 [patent_no_of_words] => 22899 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 115 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16033465 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13929127 [patent_doc_number] => 20190048079 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-02-14 [patent_title] => Methods and Compositions Involving NKG2D Inhibitors and Cancer [patent_app_type] => utility [patent_app_number] => 16/029129 [patent_app_country] => US [patent_app_date] => 2018-07-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 31681 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16029129 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17377015 [patent_doc_number] => 11235004 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-02-01 [patent_title] => Lymphocyte cell lines and uses thereof [patent_app_type] => utility [patent_app_number] => 16/023310 [patent_app_country] => US [patent_app_date] => 2018-06-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 51 [patent_figures_cnt] => 51 [patent_no_of_words] => 31792 [patent_no_of_claims] => 26 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 39 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16023310 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16913931 [patent_doc_number] => 20210187023 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-06-24 [patent_title] => Compositions And Methods For Enhancing Immunotherapy [patent_app_type] => utility [patent_app_number] => 16/621660 [patent_app_country] => US [patent_app_date] => 2018-06-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14695 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -75 [patent_words_short_claim] => 21 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16621660 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17082103 [patent_doc_number] => 20210277109 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-09-09 [patent_title] => ANTI-ROR1 ANTIBODIES AND METHODS OF MAKING AND USING THEREOF [patent_app_type] => utility [patent_app_number] => 16/615116 [patent_app_country] => US [patent_app_date] => 2018-06-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8524 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16615116 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17148428 [patent_doc_number] => 11141480 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-10-12 [patent_title] => Dosing parameters for CD47 targeting therapies to hematologic malignancies [patent_app_type] => utility [patent_app_number] => 16/619387 [patent_app_country] => US [patent_app_date] => 2018-06-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 10 [patent_no_of_words] => 15210 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 29 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16619387 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18777841 [patent_doc_number] => 11819517 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-11-21 [patent_title] => Methods of using tumor infiltrating lymphocytes in double-refractory melanoma [patent_app_type] => utility [patent_app_number] => 16/618039 [patent_app_country] => US [patent_app_date] => 2018-06-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 43 [patent_figures_cnt] => 42 [patent_no_of_words] => 69886 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 61 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16618039 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17200155 [patent_doc_number] => 20210340250 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-11-04 [patent_title] => COMPOSITIONS COMPRISING A COMBINATION OF AN ANTI-LAG-3 ANTIBODY, A PD-1 PATHWAY INHIBITOR, AND AN IMMUNOTHERAPEUTIC AGENT [patent_app_type] => utility [patent_app_number] => 16/616569 [patent_app_country] => US [patent_app_date] => 2018-05-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17515 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 16 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16616569 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19717542 [patent_doc_number] => 12203065 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-01-21 [patent_title] => Method for culturing natural killer cell, using transformed T cell [patent_app_type] => utility [patent_app_number] => 16/613601 [patent_app_country] => US [patent_app_date] => 2018-05-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 79 [patent_figures_cnt] => 104 [patent_no_of_words] => 13221 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 56 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16613601 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13840647 [patent_doc_number] => 20190023808 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-01-24 [patent_title] => TARGETING O-ACETYLATED GD2 GANGLIOSIDE AS A NEW THERAPEUTIC AND DIAGNOSTIC STRATEGY FOR CANCER STEM CELLS CANCER [patent_app_type] => utility [patent_app_number] => 15/984980 [patent_app_country] => US [patent_app_date] => 2018-05-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12905 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 82 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15984980 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17268518 [patent_doc_number] => 11193938 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-12-07 [patent_title] => Cancer antigen targets and uses thereof [patent_app_type] => utility [patent_app_number] => 15/966992 [patent_app_country] => US [patent_app_date] => 2018-04-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 64 [patent_figures_cnt] => 41 [patent_no_of_words] => 51749 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 81 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15966992 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13386407 [patent_doc_number] => 20180244745 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-08-30 [patent_title] => EPHA3 AND MULTI-VALENT TARGETING OF TUMORS [patent_app_type] => utility [patent_app_number] => 15/958608 [patent_app_country] => US [patent_app_date] => 2018-04-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18144 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15958608 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13383653 [patent_doc_number] => 20180243368 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-08-30 [patent_title] => MOLECULAR SIGNATURE OF CANCER [patent_app_type] => utility [patent_app_number] => 15/957445 [patent_app_country] => US [patent_app_date] => 2018-04-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21087 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15957445 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14105103 [patent_doc_number] => 20190094227 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-03-28 [patent_title] => DISEASE-ASSOCIATED ANTIGENS AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 15/954324 [patent_app_country] => US [patent_app_date] => 2018-04-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 64161 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15954324 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17150582 [patent_doc_number] => 11143653 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-10-12 [patent_title] => Methods and materials for assessing immune system profiles [patent_app_type] => utility [patent_app_number] => 15/953129 [patent_app_country] => US [patent_app_date] => 2018-04-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 23 [patent_figures_cnt] => 21 [patent_no_of_words] => 10687 [patent_no_of_claims] => 3 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 117 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15953129 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17664120 [patent_doc_number] => 11357796 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-06-14 [patent_title] => Treatment using chimeric receptor T cells incorporating optimized polyfunctional T cells [patent_app_type] => utility [patent_app_number] => 15/944484 [patent_app_country] => US [patent_app_date] => 2018-04-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 25 [patent_figures_cnt] => 56 [patent_no_of_words] => 22443 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 104 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15944484 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18353962 [patent_doc_number] => 11642346 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-05-09 [patent_title] => Combination therapy for treating cancer [patent_app_type] => utility [patent_app_number] => 16/499476 [patent_app_country] => US [patent_app_date] => 2018-03-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 41 [patent_no_of_words] => 32757 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 31 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16499476 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16613710 [patent_doc_number] => 20210032363 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-02-04 [patent_title] => METHODS OF TREATING T CELL EXHAUSTION BY INHIBITING OR MODULATING T CELL RECEPTOR SIGNALING [patent_app_type] => utility [patent_app_number] => 16/499760 [patent_app_country] => US [patent_app_date] => 2018-03-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 31666 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -47 [patent_words_short_claim] => 33 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16499760 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13522773 [patent_doc_number] => 20180312929 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-11-01 [patent_title] => METHODS AND COMPOSITIONS RELATED TO T-CELL ACTIVITY [patent_app_type] => utility [patent_app_number] => 15/937044 [patent_app_country] => US [patent_app_date] => 2018-03-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 45389 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15937044 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13425107 [patent_doc_number] => 20180264096 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-09-20 [patent_title] => Prophylactic Vaccine to Tumor Angiogenesis [patent_app_type] => utility [patent_app_number] => 15/924629 [patent_app_country] => US [patent_app_date] => 2018-03-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4848 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 58 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15924629 [rel_patent_id] =>[rel_patent_doc_number] =>)